Jupiter, Florida — January 28, 2026 — Leads & Copy — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is launching a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line.
The initiative reinforces Jupiter’s dual-engine strategy, which combines a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business. As GLP-1 adoption accelerates globally, Jupiter sees an opportunity to serve a growing population seeking science-backed, pharmaceutical-grade solutions that extend beyond weight loss alone.
GLP-1 receptor agonists have transformed the landscape of obesity and metabolic health by driving weight loss. However, increasing clinical and consumer awareness highlights that GLP-1-induced weight loss can place physiological demands on mitochondrial energy production, lean tissue preservation, and neuro-gut inflammatory balance. Jupiter believes these biological pressures represent an unmet need as millions of individuals seek solutions that support long-term metabolic resilience and healthspan.
“GLP-1 therapies drive weight loss, but biology still must sustain it,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. The Aesthetic Surgery Journal recently reported that patients with significant weight loss may look up to 5 years older than peers without such weight changes, in addition to an increase of 4,600% of the search term “Ozempic face” on the internet. Rosén stated that using AI, a combination of their Nugevia™ MND and Nugevia™ PWR products is indicated to be a possible solution to avoid this issue.
According to Rosén, the company’s science is centered on mitochondrial health, neuroinflammation, and cellular resilience. With this strategic step, Nugevia™ is positioning itself to support the biological systems that are stressed during rapid metabolic change.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated improved bioavailability. Nugevia™ brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, including indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS.
Source: Jupiter Neurosciences
